Static magnetic fields impair angiogenesis and growth of solid tumors in vivo

Donata Strelczyk1, Martin E Eichhorn, Siiri Luedemann

  • 1Walter-Brendel-Center for Experimental Medicine (WBex), Campus Grosshadern, University of Munich (LMU), Munich, Germany.

Insights

Static magnetic fields (SMFs) significantly inhibit tumor growth and angiogenesis by reducing blood flow and vessel maturation. This SMF therapy shows promise as an anticancer strategy and chemotherapy sensitizer.

Area of Science:

  • Oncology
  • Biophysics
  • Medical Physics

Background:

  • Static magnetic fields (SMFs) affect tumor blood flow and platelet activation.
  • The functional impact of SMFs on tumor progression remains largely unexplored.

Purpose of the Study:

  • To investigate the effects of prolonged SMF exposure on tumor angiogenesis and growth.
  • To evaluate SMFs as a potential anticancer therapeutic strategy.

Main Methods:

  • Experiments utilized dorsal skinfold chambers in Syrian Golden hamsters with A-Mel-3 melanomas.
  • Animals were exposed to a 586 mT SMF for three hours, with control groups receiving no SMF.
  • In vivo-fluorescence microscopy and planimetry assessed tumor angiogenesis, microcirculation, and growth over seven days.

Main Results:

  • SMF exposure significantly retarded tumor growth by approximately 30%.
  • Reduced functional vessel density, vessel diameters, and red blood cell velocity were observed in SMF-exposed tumors.
  • Increased peri- and intratumoral edema indicated enhanced tumor microvessel leakiness.

Conclusions:

  • SMFs inhibit tumor growth and angiogenesis, suggesting a role in anti-cancer therapy.
  • SMF-induced changes may enhance drug delivery, positioning it as a potential chemotherapy sensitizer.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...